EA200301204A1 - Фармацевтически активные производные нуклеозида, способ их получения, их применение (варианты) и содержащая их фармацевтическая композиция, способ профилактики и/или лечения заболеваний и нарушений млекопитающих (варианты), комбинация лекарственных средств и ее применение (варианты) - Google Patents

Фармацевтически активные производные нуклеозида, способ их получения, их применение (варианты) и содержащая их фармацевтическая композиция, способ профилактики и/или лечения заболеваний и нарушений млекопитающих (варианты), комбинация лекарственных средств и ее применение (варианты)

Info

Publication number
EA200301204A1
EA200301204A1 EA200301204A EA200301204A EA200301204A1 EA 200301204 A1 EA200301204 A1 EA 200301204A1 EA 200301204 A EA200301204 A EA 200301204A EA 200301204 A EA200301204 A EA 200301204A EA 200301204 A1 EA200301204 A1 EA 200301204A1
Authority
EA
Eurasian Patent Office
Prior art keywords
uridine
esters
combination
deoxyuridine
acid residue
Prior art date
Application number
EA200301204A
Other languages
English (en)
Inventor
Руди Зузило
Original Assignee
Тромсдорф ГмбХ унд Ко.КГ Арцнаймиттель
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тромсдорф ГмбХ унд Ко.КГ Арцнаймиттель filed Critical Тромсдорф ГмбХ унд Ко.КГ Арцнаймиттель
Priority claimed from PCT/EP2002/004725 external-priority patent/WO2002088159A1/en
Publication of EA200301204A1 publication Critical patent/EA200301204A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)

Abstract

Настоящее изобретение относится к новым сложным эфирам уридина общей формулы (I), где R означает остаток карбоновой кислоты, предпочтительно остаток жирной кислоты, и R' означает водород или гидроксильную группу, к их применению в качестве фармацевтически активных агентов против ряда заболеваний, к способу получения упомянутых сложных эфиров уридина и к фармацевтическим композициям, содержащим по крайней мере один сложный эфир уридина в качестве активного компонента. Настоящее изобретение относится также к комбинации лекарственных средств, включающей в себя свободные жирные кислоты и/или сложные эфиры жирных кислот и уридин, дезоксиуридин, монофосфат уридина и/или монофосфат дезоксиуридина, и к применению такой комбинации лекарственных средств.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200301204A 2001-04-30 2002-04-29 Фармацевтически активные производные нуклеозида, способ их получения, их применение (варианты) и содержащая их фармацевтическая композиция, способ профилактики и/или лечения заболеваний и нарушений млекопитающих (варианты), комбинация лекарственных средств и ее применение (варианты) EA200301204A1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP01110608 2001-04-30
US28809001P 2001-05-03 2001-05-03
EP01124879 2001-10-18
US33042901P 2001-10-22 2001-10-22
PCT/EP2002/004725 WO2002088159A1 (en) 2001-04-30 2002-04-29 Pharmaceutically active uridine esters

Publications (1)

Publication Number Publication Date
EA200301204A1 true EA200301204A1 (ru) 2004-04-29

Family

ID=32598659

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200301204A EA200301204A1 (ru) 2001-04-30 2002-04-29 Фармацевтически активные производные нуклеозида, способ их получения, их применение (варианты) и содержащая их фармацевтическая композиция, способ профилактики и/или лечения заболеваний и нарушений млекопитающих (варианты), комбинация лекарственных средств и ее применение (варианты)

Country Status (5)

Country Link
US (4) US7560442B2 (ru)
JP (1) JP4880190B2 (ru)
EA (1) EA200301204A1 (ru)
EE (1) EE201100023A (ru)
RS (2) RS51031B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20050158258A1 (en) * 2004-01-21 2005-07-21 Mary Kay Inc. Methods and compositions for the treatment of skin changes associated with aging and environmental damage
US8084500B2 (en) * 2005-01-14 2011-12-27 Nutrition Therapeutics, Inc. Method of using catalpic acid to treat dyslipidemia
US7687544B2 (en) * 2005-01-14 2010-03-30 Nutrition Therapeutics, Inc. Method of using catalpic acid to treat type 2 diabetes and associated disorders
US8420122B2 (en) * 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
JP5592647B2 (ja) * 2006-04-28 2014-09-17 メルク・シャープ・アンド・ドーム・コーポレーション 制御された析出による６，６−ジメチル−３−アザ−ビシクロ［３．１．０］ヘキサン−アミド化合物の析出および単離のための方法、ならびにこれを含む医薬処方物
WO2009097596A1 (en) * 2008-01-31 2009-08-06 Paul Griffin Compositions and methods for the treatment of chronic infections
US8329663B2 (en) * 2008-01-31 2012-12-11 Paul Griffin Compositions and methods for the treatment of chronic infections
CN103251631A (zh) * 2008-05-13 2013-08-21 根梅迪卡治疗公司 用于治疗代谢性病症的水杨酸盐(酯)缀合物
US8950583B2 (en) 2008-12-06 2015-02-10 Ermes Medical Company Limited Method to remove heavy metals from a mammal
CA2755069A1 (en) * 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
WO2010106083A1 (en) * 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Combination therapies for treating metabolic disorders
US20110076246A1 (en) * 2009-09-28 2011-03-31 Haley Boyd E Thiol-containing compounds for the removal of elements from contaminated milieu and methods of use
US8575218B2 (en) * 2009-09-28 2013-11-05 The University Of Kentucky Research Foundation Thiol-containing compounds for the removal of elements from tissues and formulations therefor
US8426368B2 (en) * 2010-03-25 2013-04-23 The University Of Kentucky Research Foundation Method of ameliorating oxidative stress and supplementing the diet
JP2012041283A (ja) * 2010-08-17 2012-03-01 Porien Project Kk 血管新生抑制剤
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
CN105612155A (zh) * 2012-05-10 2016-05-25 塞利克斯比奥私人有限公司 治疗局部疼痛的组合物和方法
JP6463750B2 (ja) * 2013-10-23 2019-02-06 ケムジーンズ コーポレーション 固体表面上に生体分子をより強力に固定化するためのジチオラン官能化ヌクレオシドアミダイトおよび担体
EP3002010A1 (en) * 2014-09-30 2016-04-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Food intake, body weight and glucose metabolism regulation by modulation of P2Y6 receptor signaling
WO2016008603A1 (en) * 2014-07-16 2016-01-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Food intake, body weight and glucose metabolism regulation by modulation of p2y6 receptor signaling
JP6949002B6 (ja) 2015-08-05 2021-11-17 メトロ インターナショナル バイオテック，エルエルシー ニコチンアミドモノヌクレオチド誘導体及びそれらの使用
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
WO2017155386A1 (en) * 2016-03-08 2017-09-14 N.V. Nutricia Method for treating brain atrophy
AU2019214858B2 (en) 2018-01-30 2023-02-02 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
US10618927B1 (en) * 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
JP2024520410A (ja) 2021-05-27 2024-05-24 メトロ インターナショナル バイオテック，エルエルシー ニコチン酸モノヌクレオチド及びそのエステルの結晶性固体並びに作製及び使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8319073D0 (en) * 1983-07-14 1983-08-17 Efamol Ltd Fatty acid compositions
EP0339075B1 (en) * 1987-10-28 1993-08-18 Pro-Neuron, Inc. Acylated uridine and cytidine and uses thereof
US5736531A (en) 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents

Also Published As

Publication number Publication date
RS20100077A (en) 2010-10-31
US7417034B2 (en) 2008-08-26
US20050043269A1 (en) 2005-02-24
YU76503A (sh) 2006-05-25
US7915234B2 (en) 2011-03-29
EE201100023A (et) 2011-08-15
US20040121979A1 (en) 2004-06-24
JP2004531543A (ja) 2004-10-14
JP4880190B2 (ja) 2012-02-22
US7560442B2 (en) 2009-07-14
US7396826B2 (en) 2008-07-08
US20050043394A1 (en) 2005-02-24
RS51031B (sr) 2010-10-31
US20050065110A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
EA200301204A1 (ru) Фармацевтически активные производные нуклеозида, способ их получения, их применение (варианты) и содержащая их фармацевтическая композиция, способ профилактики и/или лечения заболеваний и нарушений млекопитающих (варианты), комбинация лекарственных средств и ее применение (варианты)
BR0209320A (pt) ésteres de uridina farmaceuticamente ativos
NO20013367L (no) Colchinolderivater som vaskulorskadende midler
DE60211935D1 (de) Alkandiol derivate zur behandlung von knochenkrankheiten
DE60140491D1 (de) Verwendung einer pharmazeutischen Zusammensetzung mit einem Para-Aminophenylessigsäurederivat für die Behandlung von entzündlichen Erkrankungen des Magen-Darmtrakts
ES2071621T3 (es) Enantiomero dextrogiro del alfa-(tetrahidro-4,5,6,7-tieno-(3,2-c)-piridil-5)(cloro-2-fenil) acetato de metilo, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen.
HU207298B (en) Process for producing perhydro-izoquinolin-amino-acid derivatives and pharmaceutical compositions containing them
EA199800350A1 (ru) Биоадгезивная твердая дозированная лекарственная форма
HUP9901319A2 (hu) 9-Hidroxi-riszperidon zsírsavészterek vizes szuszpenziói, előállításuk és alkalmazásuk
DK0752855T3 (da) Anvendelse af fedtsyreestere som bioadhæsive substanser
IT1256345B (it) Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
EP0291245B1 (en) Benzoylaminophenoxybutanoic acid derivatives
HUP0003571A2 (hu) 6,9-Hídkötésű eritromicin-származékok
HUP0203236A2 (hu) Orális és helyi beadásra szolgáló gyógyszerkészítmények
PT1383756E (pt) Derivados de cumarina a utilizar como anticoagulantes
BR0008776A (pt) Análogos de prostaglandinas fp-seletivosinsaturados c16
KR0135723B1 (ko) 신규한 에스큘레틴 유도체 및 약학 조성물
ES2181901T3 (es) Esteres y amidas como inhibidores de fosfolipasa a2(pla2).
US4661519A (en) Method for dermatological application
FR2395272A1 (fr) Nouveaux medicaments derives de l'acide amidinopenicillanique
HUP9903632A2 (hu) Neuraminsav vegyületek, azokat tartalmazó gyógyszerkészítmények és eljárás e készítmények előállítására
JPS6117574A (ja) カルシウム拮抗活性のある１‐〔ビス‐（４‐ルオロフエニル）‐メチル〕‐４‐（３‐フエニル‐２‐プロペニル）‐ヘキサヒドロ‐１ｈ‐１，４‐ジアゼピンとその製法及びそれを含有する医薬組成物
ATE165822T1 (de) Chinolin-4-carbonylguanidin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
BG100246A (en) N-substituted azaheterocylic carboxylic acids and their esters
HUP0301010A2 (hu) A koleszteril-észter és a viaszészter szintézisét egyaránt gátló vegyületek faggyúmirigy-betegségek kezeléséhez és ezeket tartalmazó gyógyszerkészítmények